Heghine Khachatryan: Advances in Targeted Therapy Transforming TTP Management at ASH Highlights 2026
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:
“ASH Highlights 2026 – Advances in Thrombotic Thrombocytopenic Purpura (TTP)
One of the most impactful sessions today focused on emerging therapeutic strategies in immune TTP (iTTP) and congenital TTP (cTTP), particularly CD38-targeted therapy and recombinant ADAMTS13 replacement.
Daratumumab in Immune TTP (iTTP)
Data from the international, multicenter DarTTP study demonstrated:
- Rapid ADAMTS13 remission in 75% of patients with iTTP who were refractory or intolerant to rituximab and other immunosuppressive therapies
- Sustained remission (>6 months) in approximately two-thirds of responders
- Targeting CD38+ plasma cells offers a promising strategy in cases where B-cell depletion alone is insufficient
These findings represent an important advancement in the management of refractory iTTP and provide renewed hope for patients at high risk of relapse.
Congenital TTP (cTTP)
The session also highlighted a clinical case discussion and phase 3 data on recombinant ADAMTS13 (rADAMTS13) replacement therapy:
- Demonstrated favorable efficacy and safety profile
- Approved in the US, EU, and Japan for both prophylactic and on-demand use
- Represents a paradigm shift in long-term cTTP management, reducing dependence on plasma infusions
This lecture clearly underscored that TTP treatment is entering a new era of mechanism-based and targeted therapy.
Integrating these advances into national practice remains crucial, particularly with regard to laboratory capacity, ADAMTS13 monitoring, and access to innovative therapeutics in our region.”
Find more posts featuring Heghine Khachatryan on Hemostasis Today.
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge
-
Oct 19, 2026, 16:13Javier M. Floren: When Immune Cells Move With Their Environment